SP/NK-1R系统在乳腺癌中的研究进展

doi:10.11904/j.issn.1002-3070.2024.04.009

Abstract

Abstract: In recent years,although many advances have been made in the treatment of breast cancer,its incidence is still on the rise,and the search for new drug targets and biomarkers has become a research hotspot.More and more clinical studies are paying attention to the interaction between tumor cells and tumor microenvironment,and it is believed that tumor microenvironment plays a crucial role in the progression of malignant tumors.Substance P(SP)can participate in the process of carcinogenesis and play a crucial key role in maintaining the tumor microenvironment.Neurokinin 1 receptor(NK-1R)is expressed in the cytoplasm of tumor cells and is significantly associated with many tumor characteristics.SP induces tumor cell proliferation,angiogenesis and migration through its receptor NK-1R,and exerts anti-apoptotic effects.In future treatment plan,whether NK-1R antagonists can be used to provide more accurate targets for the diagnosis and treatment of breast cancer has become a hot topic.This article reviews the research status of SP/NK-1R system in breast cancer.

Key words: Breast cancer, Substance P/Neurokinin 1 receptor system, Neurokinin 1 receptor antagonist, Targeted therapy

CLC Number:

R737.9

SHAO Yuming, ZHU Kunbing, ZHANG Jie. Research progress of SP/NK-1R system in breast cancer[J]. Journal of Practical Oncology, 2024, 38(4): 268-272.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2024.04.009

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2024/V38/I4/268

References

1 Wilkinson L,Gathani T.Understanding breast cancer as a global health concern[J].Br J Radiol,2022,95(1130):20211033.
2 Bray F,Laversanne M,Sung H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263.
3 Muñoz M,Coveñas R.Involvement of substance P and the NK-1 receptor in cancer progression[J].Peptides,2013,48:1-9.
4 Tokuda M,Miyamoto R,Nagaoka S,et al.Substance P enhances expression of lipopolysaccharide-induce inflammatory factors in dental pulp cells[J].J Endod,2004,30(11):770-773.
5 Mehboob R,Gilani SA,Hassan A,et al.Prognostic significance of substance P/Neurokinin 1 receptor and its association with hormonal receptors in breast carcinoma[J].Biomed Res Int,2021,2021:5577820.
6 Muñoz M,Coveñas R.Involvement of substance P and the NK-1 receptor in human pathology[J].Amino Acids,2014,46(7):1727-1750.
7 徐竟捷.Neurokinin-1受体在非小细胞肺癌增殖、迁移和凋亡过程中的作用及其信号机制研究[D].兰州:兰州大学,2020.
8 Muñoz M,Coveñas R.The neurokinin-1 receptor antagonist aprepitant:an intelligent bullet against cancer?[J].Cancers(Basel),2020,12(9):2682.
9 Davoodian M,Boroumand N,Bahar MM,et al.Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in breast cancer[J].Mol Biol Rep,2019,46(1):1285-1293.
10 Muñoz M,Rosso M,Coveñas R.Triple negative breast cancer:How neurokinin-1 receptor antagonists could be used as a new therapeutic approach[J].Mini Rev Med Chem,2020,20(5):408-417.
11 Muñoz M,Rosso M,Coveñas R.Neurokinin-1 receptor antagonists against hepatoblastoma[J].Cancers(Basel),2019,11(9):1258.
12 Muñoz M,González-Ortega A,Salinas-Martín MV,et al.The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer[J].Int J Oncol,2014,45(4):1658-1672.
13 Gillespie E,Leeman SE,Watts LA,et al.Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer[J].Proc Natl Acad Sci U S A,2011,108(42):17420-17425.
14 Zhou YL,Zhao LL,Xiong T,et al.Roles of full-length and truncated neurokinin-1 receptors on tumor progression and distant metastasis in human breast cancer[J].Breast Cancer Res Treat,2013,140(1):49-61.
15 Berger M,Neth O,Ilmer M,et al.Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo[J].J Hepatol,2014,60(5):985-994.
16 Al-Keilani MS,Elstaty RI,Alqudah MA,et al.Immunohistochemical expression of substance P in breast cancer and its association with prognostic parameters and Ki-67 index[J].PLoS One,2021,16(6):e0252616.
17 Wang F,Liu SS,Liu JQ,et al.SP promotes cell proliferation in esophageal squamous cell carcinoma through the NK1R/Hes1 axis[J].Biochem Biophys Res Commun,2019,514(4):1210-1216.
18 Ge CT,Huang HM,Huang FY,et al.Neurokinin-1 receptor is an effective oxidative stress through mitochondrial calcium overload[J].Proc Natl Acad Sci U S A,2019,116(39):19635-19645.
19 Steinhoff MS,Mentzer BV,Geppetti P,et al.Tachykinins and their receptors:contributions to physiological control and the mechanisms of disease[J].Physiol Rev,2014,94(1):265-301.
20 Garcia-Recio S,Fuster G,Fernandez-Nogueira P,et al.Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer[J].Cancer Res,2013,73(21):6424-6434.
21 Li JY,Zeng Q,Zhang YX,et al.Neurokinin-1 receptor mediated breast cancer cell migration by increased expression of MMP-2 and MMP-14[J].Eur J Cell Biol,2016,95(10):368-377.
22 Ma J,Yuan SF,Cheng JX,et al.Substance P promotes the progression of endometrial adenocarcinoma[J].Int J Gynecol Cancer,2016,26(5):845-850.
23 Deng XT,Tang SM,Wu PY,et al.SP/NK-1R promotes gallbladder cancer cell proliferation and migration[J].J Cell Mol Med,2019,23(12):7961-7973.
24 Kwatra SG,Boozalis E,Huang AH,et al.Proteomic and phosphoproteomic analysis reveals that neurokinin-1 receptor(NK1R)blockade with aprepitant in human keratinocytes activates a distinct subdomain of EGFR signaling:implications for the anti-pruritic activity of NK1R antagonists[J].Medicines(Basel),2019,6(4):114.
25 Bashash D,Safaroghli-Azar A,Bayati S,et al.Neurokinin-1 receptor(NK1R)inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis:shedding new light on resistance to aprepitant[J].Int J Biochem Cell Biol,2018,103:105-114.
26 Robinson P,Kasembeli M,Bharadwaj U,et al.Substance P receptor signaling mediates doxorubicin-induced cardiomyocyte apoptosis and triple-negative breast cancer chemoresistance[J].Biomed Res Int,2016,2016:1959270.
27 Un H,Ugan RA,Kose D,et al.A novel effect of aprepitant:protection for cisplatin-induced nephrotoxicity and hepatotoxicity[J].Eur J Pharmacol,2020,880:173168.
28 Rodriguez E,Pei GS,Kim ST,et al.Substance P antagonism as a novel therapeutic option to enhance efficacy of cisplatin in triple negative breast cancer and protect PC12 cells against cisplatin-induced oxidative stress and apoptosis[J].Cancers(Basel),2021,13(15):3871.
29 Xiong J,Zhao GF,Yang SL,et al.Efficacy,tolerability and pharmacokinetic impact of aprepitant in sarcoma patients receiving ifosfamide and doxorubicin chemotherapy:a randomized controlled trial[J].Adv Ther,2019,36(2):355-364.

[1]	LI Qianni, XU Lingyan, LI Jian, YAO Xuepei, LIU Meina. Trend analysis of a longitudinal evaluation for multidimensional treatment quality of breast cancer [J]. Journal of Practical Oncology, 2024, 38(4): 213-220.
[2]	GAO Guangqiang, WANG Falin, LI Juan, TIAN Hong, GUO Sijia, YU Xiaolan, YANG Tingting, LIU Jiaren. β-Ionone suppresses breast cancer cell proliferation through the NF-κB pathway [J]. Journal of Practical Oncology, 2024, 38(4): 254-261.
[3]	YIN Haiyan, CHUN Zhiming, MA Qiaojun, CHENG Han, DING Gaoheng, LIU Yuqin, ZHANG Haiyan. Epidemic characteristics of female breast cancer in cancer registration areas of Gansu province in 2019 and trend analysis from 2010 to 2019 [J]. Journal of Practical Oncology, 2024, 38(3): 141-148.
[4]	Breast Oncology Group of Heilongjiang Medical Association. Expert consensus on clinicopathological diagnosis of breast cancer with low expression of HER2 in Heilongjiang province(2024 edition) [J]. Journal of Practical Oncology, 2024, 38(2): 71-78.
[5]	MENG Fangang, CHEN Fei, ZHEN Lijun. Effects of DLX2 on proliferation,migration,invasion,apoptosis of breast cancer cells and characteristics of breast cancer stem cells [J]. Journal of Practical Oncology, 2024, 38(2): 88-95.
[6]	ZHENG Pengfei, DONG Liangpeng, GAO Yanxin, ZHANG Yifu, QIN Shuang. Effect of interleukin-38 to CD8⁺T lymphocyte function in patients with breast cancer [J]. Journal of Practical Oncology, 2024, 38(1): 30-36.
[7]	XIE Junling. Research progress of activated leukocyte adhesion molecule in breast cancer [J]. Journal of Practical Oncology, 2024, 38(1): 45-49.
[8]	FENG Churan, CAO Jianzhao, CHEN Ziyin, ZHANG Daxin, LU Hailing. Research progress on radiation-induced cardiac injury in breast cancer and its preventive measures [J]. Journal of Practical Oncology, 2023, 37(6): 513-518.
[9]	ZHAO Shilu, PANG Da. Bioinformatics screening and analysis of prognostic genes in breast cancer [J]. Journal of Practical Oncology, 2023, 37(5): 422-428.
[10]	FAN Tingting, DING Danni, ZHAO Zixue, YU Yang, HAN Fengjuan. Fatty acid metabolism and ovarian cancer [J]. Journal of Practical Oncology, 2023, 37(5): 429-433.
[11]	CHU Sitong, XU Qingyong. Research progress on immunotherapy resistance mechanisms of triple-negative breast cancer [J]. Journal of Practical Oncology, 2023, 37(5): 449-453.
[12]	WANG Xinping, ZHANG Ziyun, WANG Xuedong. Research progress on the roles of non-coding RNA in chemotherapy resistance of breast cancer [J]. Journal of Practical Oncology, 2023, 37(5): 454-458.
[13]	LU Hongnan, XIA Bingshu, QIAO Kun, ZHANG Shiyuan, HUANG Yuanxi, LU Xiangshi. Relationship between GAS1,immunotherapy and drug sensitivity in breast cancer [J]. Journal of Practical Oncology, 2023, 37(4): 351-359.
[14]	CHEN Fei, WANG Ying, ZENG Chuanqin. Expression of B7-H4 in breast cancer tissues and its correlation with axillary lymph node metastasis in patients after neoadjuvant chemotherapy [J]. Journal of Practical Oncology, 2023, 37(4): 360-366.
[15]	LI Fucheng, JIA Siyuan, BA Yuling, LUO Danli, XIAO Min. Research progress of immune checkpoint inhibitors in neoadjuvant therapy of early breast cancer [J]. Journal of Practical Oncology, 2023, 37(4): 367-371.

Research progress of SP/NK-1R system in breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments